Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Expands By 11.4%

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 350,600 shares, a growth of 11.4% from the September 30th total of 314,700 shares. Based on an average daily trading volume, of 110,600 shares, the days-to-cover ratio is presently 3.2 days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $31,000. SG Americas Securities LLC purchased a new stake in Harvard Bioscience in the third quarter worth about $36,000. Cubist Systematic Strategies LLC bought a new stake in Harvard Bioscience during the 2nd quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Harvard Bioscience during the 1st quarter worth approximately $54,000. Finally, Brighton Jones LLC purchased a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $68,000. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Trading Down 4.1 %

Shares of Harvard Bioscience stock traded down $0.10 during trading on Thursday, reaching $2.35. 62,683 shares of the stock were exchanged, compared to its average volume of 113,688. Harvard Bioscience has a 1 year low of $2.30 and a 1 year high of $5.56. The firm has a market cap of $102.06 million, a price-to-earnings ratio of -11.75 and a beta of 1.29. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48. The stock’s fifty day moving average is $2.64 and its 200 day moving average is $3.01.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). The business had revenue of $23.10 million during the quarter, compared to the consensus estimate of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. As a group, equities research analysts expect that Harvard Bioscience will post 0.11 earnings per share for the current fiscal year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.